

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

The following full text is a publisher's version.

For additional information about this publication click this link.

<http://hdl.handle.net/2066/208633>

Please be advised that this information was generated on 2021-02-27 and may be subject to change.

2. Molina-Molina M, Aburto M, Acosta O, Ancochea J, Rodríguez-Portal JA, Sauleda J, *et al.* Importance of early diagnosis and treatment in idiopathic pulmonary fibrosis. *Expert Rev Respir Med* 2018;12:537–539.
3. Lamas DJ, Kawut SM, Bagiella E, Philip N, Arcasoy SM, Lederer DJ. Delayed access and survival in idiopathic pulmonary fibrosis: a cohort study. *Am J Respir Crit Care Med* 2011;184:842–847.
4. Spagnolo P, Tzouvelekis A, Bonella F. The management of patients with idiopathic pulmonary fibrosis. *Front Med (Lausanne)* 2018;5:148.
5. Kolb M, Richeldi L, Behr J, Maher TM, Tang W, Stowasser S, *et al.* Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. *Thorax* 2017;72:340–346.
6. Fletcher SV, Jones MG, Renzoni EA, Parfrey H, Hoyles RK, Spinks K, *et al.* Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice. *ERJ Open Res* 2018;4:00049–2018.
7. Schoenheit G, Becattelli I, Cohen AH. Living with idiopathic pulmonary fibrosis: an in-depth qualitative survey of European patients. *Chron Respir Dis* 2011;8:225–231.
8. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, *et al.*; American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society. Diagnosis of idiopathic pulmonary fibrosis: an official ATS/ERS/JRS/ALAT clinical practice guideline. *Am J Respir Crit Care Med* 2018; 198:e44–e68.
9. Wells AU, Kokosi MA. Subclinical interstitial lung abnormalities: toward the early detection of idiopathic pulmonary fibrosis? *Am J Respir Crit Care Med* 2016;194:1445–1446.
10. Sgalla G, Walsh SLF, Sverzellati N, Fletcher S, Cerri S, Dimitrov B, *et al.* “Velcro-type” crackles predict specific radiologic features of fibrotic interstitial lung disease. *BMC Pulm Med* 2018;18:103.
11. Sellarés J, Hernández-González F, Lucena CM, Paradela M, Brito-Zerón P, Prieto-González S, *et al.* Auscultation of Velcro crackles is associated with usual interstitial pneumonia. *Medicine (Baltimore)* 2016;95:e2573.
12. Cottin V, Cordier JF. Velcro crackles: the key for early diagnosis of idiopathic pulmonary fibrosis? *Eur Respir J* 2012;40:519–521.
13. Vyshedskiy A, Bezares F, Paciej R, Ebril M, Shane J, Murphy R. Transmission of crackles in patients with interstitial pulmonary fibrosis, congestive heart failure, and pneumonia. *Chest* 2005;128: 1468–1474.
14. Würtemberger G, Murphy Jun RLH. *Auskultationskurs Lunge, Audio-CD mit Begleitheft.* Stuttgart, Germany: Thieme; 1997.
15. Key AL, Holt K, Warburton CJ, Walker PP, Earis JE. Use of zonal distribution of lung crackles during inspiration and expiration to assess disease severity in idiopathic pulmonary fibrosis. *Postgrad Med J* 2018;94:381–385.
16. Sgalla G, Larici AR, Sverzellati N, Bartholmai B, Walsh SLF, Nikolic D, *et al.* Quantitative analysis of lung sounds for monitoring idiopathic pulmonary fibrosis: a prospective pilot study. *Eur Respir J* 2018;53: 1802093.

Copyright © 2019 by the American Thoracic Society

Fever in Sepsis: Still a Hot Topic

To the Editor:

With great interest, we read the paper by Bhavani and colleagues (1), who report a novel method to distinguish between sepsis phenotypes based on body temperature. Using trajectory

©This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (<http://creativecommons.org/licenses/by-nc-nd/4.0/>). For commercial usage and reprints, please contact Diane Gern (dgern@thoracic.org).

Originally Published in Press as DOI: 10.1164/rccm.201903-0484LE on March 25, 2019

modeling, the authors identify four phenotypes, each displaying distinct demographic characteristics, physiological parameters, and prognosis. The data presented reveal that the so-called hyperthermic, fast resolving patients, who presented with a high temperature that decreased rapidly afterward, had the lowest in-hospital mortality. In addition, a more swift increase in temperature was also positively related to survival. The authors plausibly argue that hyperthermic, fast resolvers may be able to mount a strong, but nevertheless well-balanced, inflammatory response, resulting in a better clinical outcome.

What is currently missing is more solid evidence for whether or not there is an immunological basis for the proposed temperature-based phenotypes. Insight into the release of so-called endogenous pyrogens (2), mainly represented by cytokines such as TNF α (tumor necrosis factor α) and IL-6, could provide the missing link between the underlying immune status and the body temperature trajectories observed.

In the experimental human endotoxemia model, *Escherichia coli* endotoxin is administered intravenously to healthy volunteers, inducing a standardized short-lasting systemic inflammatory response, which captures relevant hallmarks of the immune response observed in patients with sepsis (3). Serial measurements of cytokines and body temperature during endotoxemia allow for determination of their relationship. Using data from 20 male subjects allocated to the control group (no intervention other than bolus administration of 1 ng/kg endotoxin followed by continuous infusion of 1 ng/kg/h endotoxin over the course of 3 h) of a recent interventional study performed by our group (4), we analyzed the relationship between peak plasma cytokine concentrations and body temperature changes over time. We divided the subjects according to the median cytokine levels, resulting in 10 low and 10 high cytokine producers, and calculated the slope of the endotoxin-induced temperature increase ($\text{Temp}_{\text{slope}} = \Delta \text{ temperature increase/time to peak temperature}$).

On average, plasma concentrations of TNF α , IL-6, and IL-10 reached their maximum at 2.5, 3, and 3.5 hours after endotoxin administration, respectively, whereas peak temperatures were observed 4 hours after endotoxin. $\text{Temp}_{\text{slope}}$ strongly correlated with peak temperature (Spearman $r = 0.92$; $P < 0.0001$). In subjects who produced high levels of the proinflammatory cytokines IL-6 and TNF α , $\text{Temp}_{\text{slope}}$ was significantly higher than in low proinflammatory cytokine producers, whereas $\text{Temp}_{\text{slope}}$ did not differ between low and high producers of antiinflammatory IL-10 (Figure 1). Spearman correlation coefficients for the relationship between cytokines and $\text{Temp}_{\text{slope}}$ were $r = 0.75$ for IL-6 ($P < 0.0001$) and $r = 0.52$ for TNF α ($P = 0.02$). Furthermore, peak temperatures were reached earlier by high IL-6 and TNF α producers (high responders: 3.6 ± 0.1 vs. low responders: 4.5 ± 0.2 h [$P = 0.002$] and high responders: 3.7 ± 0.2 vs. low responders: 4.4 ± 0.2 h [$P = 0.02$], respectively). After the peak, temperatures gradually normalized, but the slope of the temperature decrease did not correlate with levels of any of the measured cytokines.

Taken together, these findings indicate that indeed higher levels of proinflammatory, but not antiinflammatory, cytokines precede a more potent and swift temperature increase. These data provide




Figure 1. Slope of the temperature increase ($\text{Temp}_{\text{slope}}$) after endotoxin administration for subjects with low and high peak levels of IL-6, TNF α (tumor necrosis factor α), and IL-10. Data are presented as box-and-whisker plots (Tukey).

an immunological basis for the hypothesis of Bhavani and colleagues, who state that hyperthermia may be the result of a more proinflammatory phenotype, whereas a less pronounced immune response might relate to a lower (or absent) temperature increase. In view of the more favorable prognosis of hyperthermic patients in whom temperature swiftly increases and quickly resolves, a more pronounced but adequately balanced proinflammatory response is of apparent benefit to the host. This further elucidates why dozens of trials using immunosuppressive agents failed to improve sepsis outcome and stresses the need for therapies aimed at maintaining or restoring a well-functioning immune system. ■

Author disclosures are available with the text of this letter at www.atsjournals.org.

Guus Pieter Leijte, M.D.*[†]
 Matthijs Kox, Ph.D.*
 Peter Pickkers, M.D., Ph.D.
 Radboud University Medical Center
 Nijmegen, the Netherlands

*These authors contributed equally and share first authorship.

[†]Corresponding author (e-mail: guus.leijte@radboudumc.nl).

References

- Bhavani SV, Carey KA, Gilbert ER, Afshar M, Verhoef PA, Churpek MM. Identifying novel sepsis subphenotypes using temperature trajectories. *Am J Respir Crit Care Med* [online ahead of print] 21 Feb 2019; DOI: 10.1164/rccm.201806-1197OC.
- Netea MG, Kullberg BJ, Van der Meer JW. Circulating cytokines as mediators of fever. *Clin Infect Dis* 2000;31(Suppl 5):S178–S184.
- van Lier D, Geven C, Leijte GP, Pickkers P. Experimental human endotoxemia as a model of systemic inflammation. *Biochimie* 2018; 159:99–106.

- Leijte GP, Kiers D, van der Heijden W, Jansen A, Gerretsen J, Boerrigter V, *et al.* Treatment with acetylsalicylic acid reverses endotoxin tolerance in humans *in vivo*: a randomized placebo-controlled study. *Crit Care Med* 2018;47:508–518.

Copyright © 2019 by the American Thoracic Society

Reply to Leijte *et al.*

From the Authors:

We thank Dr. Leijte, Dr. Kox, and Dr. Pickkers for their comments on our recent article on using temperature trajectories to identify sepsis subphenotypes (1). Using group-based trajectory modeling, we identified four subphenotypes with different demographics, physiological characteristics, and levels of inflammatory markers, and we hypothesized an immunological basis for these subphenotypes. Supporting our hypothesis of a connection between temperature and immunological markers, Leijte and colleagues present a human endotoxemia model revealing correlation between temperature slopes and levels of endogenous pyrogens (IL-6 and TNF α [tumor necrosis factor α]) in healthy volunteers after administration of *Escherichia coli* endotoxin (2). This data provide evidence for the relationship between body temperature and cytokine responses. In addition, the data use dynamic temperature measurement (i.e., temperature slopes) to study associations with cytokine levels. This finding aligns with our work indicating that dynamic measures of temperature (i.e., temperature trajectory, variability, and slopes) may have more significance than static measures.

Although the cytokine responses in this study provide an immunological basis for our hypothesis, the systemic inflammatory response is intentionally self-limited in these healthy volunteers. We believe that measurement of cytokine levels in naturally occurring sepsis would add further information to the relationship between the thermoregulatory and immunological systems. Sepsis is defined as a dysregulated immunological response to infection. After the initial endotoxin-driven cytokine storm in sepsis, there is a protracted dysregulated immunological process that follows. We propose that temperature trajectories may elucidate not only the initial cytokine response but also the sustained immunological process in patients with sepsis. For instance, hyperthermic, slow resolvers may have sustained high levels of proinflammatory cytokines, whereas hyperthermic, fast resolvers may have the same initial proinflammatory cytokine storm followed by a defervescence process. We look forward to studies such as those of Dr. Leijte, Dr. Kox, and Dr. Pickkers to illuminate the relationship between temperature and the immunological system. ■

Ⓒ This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (<http://creativecommons.org/licenses/by-nc-nd/4.0/>). For commercial usage and reprints, please contact Diane Gern (dgern@thoracic.org).

Originally Published in Press as DOI: 10.1164/rccm.201903-0631LE on March 25, 2019